title: Application of chimerism-based drug-induced tolerance to rat into mouse xenotransplantation.
abstract: The current critical shortage of human donor organs has stimulated the feasibility of the xenogenic transplantation, such as swine to primate. We have previously reported the induction of donor-specific tolerance in MHC-disparated recipient mice by using our cyclophosphamide (CP)-induced tolerance conditioning. In this study, we examined the efficacy of our CP-induced tolerance conditioning in xenogenic transplantation model. F344 rats and B10 mice were used as donors and recipients. Recipient mice were treated with donor spleen cells, CP, Busulfan and bone marrow cells, with or without prior NK-cell depletion. Donor mixed chimerism, and the presence of donor reactive T-cell population were analysed by flow cytometry. The survival of the donor skin grafts were observed after the conditioning. Donor mixed chimerism was temporary induced but terminated at 10 weeks after treatments. Donor-specific prolongation of the skin graft survival was observed after the treatments, however, grafts were rejected in the long term. NK-cell depletion, prior to the treatments, did not affect the levels of the mixed chimerism or graft prolongation. The donor-reactive recipient T-cell population was remained the same level as the untreated mice, suggesting the failure of the induction of the central T-cell tolerance. Thus, partial efficacy of our CP-induced tolerance treatments in the rat to mice xenotransplantation was observed. Our results suggested that the additional treatments were required to establish the stable xenogenic tolerance.
authors.affiliation: Department of Cardiovascular Surgery, Faculty of Medicine, Kyushu University, Fukuoka, Japan. tomita@heart.med.kyushu-u.ac.jp
authors.forename: Y
authors.initials: Y
authors.lastname: Tomita
authors.forename: I
authors.initials: I
authors.lastname: Shimizu
authors.forename: T
authors.initials: T
authors.lastname: Iwai
authors.forename: Q-W
authors.initials: QW
authors.lastname: Zhang
authors.forename: S
authors.initials: S
authors.lastname: Okano
authors.forename: T
authors.initials: T
authors.lastname: Kajiwara
authors.forename: T
authors.initials: T
authors.lastname: Onzuka
authors.forename: R
authors.initials: R
authors.lastname: Tominaga
mesh_terms: D000818:Animals; D016026:Bone Marrow Transplantation / Q000276:immunology; D003520:Cyclophosphamide / Q000494:pharmacology*; D006082:Graft Enhancement, Immunologic; D007108:Immune Tolerance / Q000187:drug effects / Q000235:genetics*; D007166:Immunosuppressive Agents / Q000494:pharmacology*; D051379:Mice; D008810:Mice, Inbred C57BL; D051381:Rats; D011916:Rats, Inbred F344; D011917:Rats, Inbred Lew; D016038:Skin Transplantation / Q000276:immunology; D013154:Spleen / Q000166:cytology / Q000276:immunology / Q000637:transplantation; D018183:Transplantation Chimera / Q000235:genetics* / Q000276:immunology; D019172:Transplantation Conditioning; D014183:Transplantation, Heterologous / Q000276:immunology*
chemical_list: D007166:Immunosuppressive Agents; D003520:Cyclophosphamide